- Oral presentations include three of the five pivotal studies from AbbVie's SELECT Phase 3 program to support regulatory submission for investigational upadacitinib in patients with moderate to severe rheumatoid arthritis
- New studies of HUMIRA® (adalimumab) add to the body of research evaluating treatment across multiple rheumatic conditions, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis and uveitis
- Thirty-five abstracts demonstrate AbbVie's leadership in immunology through commitment to advancing scientific research for patients living with rheumatic conditions
PR Newswire
NORTH CHICAGO, Ill., Oct. 8, 2018